Drug Profile
T-COVID coronavirus vaccine - Altimmune
Alternative Names: Coronavirus vaccine-Altimmune; COVID-19 vaccine-Altimmune; T-COVID coronavirus vaccine-Altimmune; T-COVIDTMLatest Information Update: 22 Apr 2022
Price :
$50
*
At a glance
- Originator Altimmune
- Class COVID-19 vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 31 Dec 2021 Discontinued - Phase-I/II for COVID-2019 infections in USA (Intranasal)
- 31 Dec 2020 Altimmune has patents pending for replication-deficient adenoviral vectored RespirVec platform technology in the US, Taiwan, Argentina, Europe and Japan
- 28 Sep 2020 Phase-I/II clinical trials in COVID-2019 infections in USA (Intranasal) before September 2020